HDAC inhibitors in cancer care

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Epigenetic modifications, including histone acetylation, are crucial in cancer development and progression.
• Histone deacetylase (HDAC) inhibitors represent a novel therapeutic strategy targeting these epigenetic alterations.

Purpose of the Study:

• To review the role of epigenetic control in cancer.
• To highlight the potential of histone deacetylase (HDAC) inhibitors as anticancer agents.
• To discuss the current status of HDAC inhibitors in clinical trials and future research directions.

Main Methods:

• Review of preclinical data on HDAC inhibitors in various cancer models.
• Analysis of clinical trial outcomes for HDAC inhibitors as monotherapies and combination treatments.
• Examination of approved HDAC inhibitors for specific cancer types.

Main Results:

• Preclinical studies demonstrate significant anticancer efficacy of HDAC inhibitors, particularly when combined with other therapies.
• Several HDAC inhibitors are under active clinical investigation, showing promise in early-phase trials.
• Vorinostat and depsipeptide are approved for refractory cutaneous T-cell lymphoma, indicating clinical validation.

Conclusions:

• HDAC inhibitors are a valuable addition to the anticancer therapeutic landscape.
• Combination therapies involving HDAC inhibitors show enhanced efficacy.
• Further research is needed to elucidate mechanisms of action and identify optimal patient populations for HDAC inhibitor treatment.